Panel of Biomarkers Proves Useful in Predicting Chronic Heart Failure Outcomes

Panel of Biomarkers Proves Useful in Predicting Chronic Heart Failure Outcomes
Critical Diagnostics' Presage® ST2 Assay once again demonstrates substantial ability to determine individual patient prognosis

San Diego, CA, USA - February 28, 2012 - Critical Diagnostics, a biomarker company focused on cardiovascular diseases, today announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model (SHFM). The paper ("Multiple Biomarkers for Risk Prediction in Chronic Heart Failure") was published online in Circulation: Heart Failure on February 23, 2012 (

The Penn Heart Failure Study (PHFS), a multi-center cohort of 1,513 outpatients with chronic heart failure, used a panel of seven biomarkers, including ST2 as measured using the Presage ST2 Assay, and compared results to the most widely validated risk score, the Seattle Heart Failure Model (SHFM). During the follow-up period of 30 months, 187 patients died, 99 had cardiac transplants, and 31 had a Ventricle Assist Device (VAD) placed. Patients in the highest one-third of the multi-marker score had a 13.7-fold increased risk of adverse outcomes compared to the lowest one-third, and this risk remained nearly 7-fold higher after adjustment for the SHFM. Moreover, the PHFS panel appropriately reclassified a significant number of patients--some 25%--into a higher risk category.

"This study provides continued support for the value of the Presage ST2 Assay in risk-stratifying patients with heart failure to better manage their condition," states James Snider, President of Critical Diagnostics.

The Presage ST2 Assay quantitatively measures the level of ST2 in blood. ST2 has been shown to be a significant predictor of mortality as well as all-cause hospitalization, mortality due to cardiovascular disease, and hospitalization due to cardiovascular disease. ST2 is prognostic for clinically important outcomes in addition to all-cause mortality. Presage ST2 Assay levels are independent and complimentary of natriuretic peptide markers and not adversely affected by such confounding factors as age, gender, body mass index and impaired renal failure.

Other papers published this year on the role of ST2 in cardiac disease include:

Kohli P, Bonaca M, Kakkar R, Kudinova A, Scirica B, Sabatine M, Murphy S, Braunwald E, Lee R, Morrow D. Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clinical Chem. 2012 58(1). (

Bayes-Genis A, Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, Cano L, Gonzalez B, Diez C, Pascual T, Elosua R, Lupon J. Combined use of High-Sensitivity ST2 and NTproBNP to Improve the Prediction of Death in Heart Failure. Euro J. of Heart Fail. 2012 Jan;14(1):32-38. (

Broch K, Ueland T, Nymo S, Kjekshus J, Hulthe J, Muntendam P, McMurray J, Wikstrand J, Cleland J, Aukrus P, Gullestad L. Soluble ST2 is Associated with Adverse Outcome in Patients with Heart Failure of Ischaemic Aetiology. Euro J. of Heart Fail. Epub Feb, 2012. (

About Critical Diagnostics and ST2
Critical Diagnostics ( develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage® ST2 Assay has been CE Marked and cleared by the US FDA. Critical Diagnostics has exclusive worldwide rights to ST2 for the diagnosis and prognosis of cardiovascular disease.

For More Information, Contact:
James Snider
Telephone: (877) 700-1250
Email: [email protected]